Biosimilars in Immunology
|出版日期||內容資訊||英文 137 Pages
|免疫學的生物相似藥 Biosimilars in Immunology|
|出版日期: 2020年02月28日||內容資訊: 英文 137 Pages||
本報告提供全球主要9個國家(美國、歐洲 (法國、德國、義大利、西班牙、英國)、日本、印度、韓國) 中，免疫藥的生物相似藥的市場相關分析，技術、產品的概要，主要的應用領域的概要，主要企業的簡介，主要市場競爭策略等調查，各國市場結構和法規、認證體制，潛在的市場規模預測，今後的技術開發、市場發展的方向性等資訊，為您概述為以下內容。
"GlobalData's Biosimilars in Immunology Thematic Analysis report combines key opinion leader insight and interviews with payers in the US, France, Germany, Italy, Spain, the UK, Japan, India and South Korea to provide an in-depth review of the biosimilars market for major autoimmune diseases."
The report includes an assessment of ongoing clinical trials, the geographical location of trial sponsors, discussion of the key players in the medical marijuana space as well as insights from industry experts discussing market challenges and considerations of stakeholders in the arena."
Europe leads the way for immunology biosimilars in the 7MM, and India is at the forefront in the emerging markets. In terms of immunology biosimilar penetration, the 5EU and India demonstrate the highest favorability towards uptake of biosimilars.
Japan and South Korea have an intermediate biosimilar penetration index, while the US market is the least favorable towards biosimilars. Pricing is a key issue for expensive-to-develop biosimilars entering an increasingly crowded autoimmune disease market.Biosimilars are intended to relieve healthcare-associated cost burden; however, the economic effects of incorporating them into clinical practice are unclear, due to increased time and staff costs required for switching patients onto biosimilars.
Pricing can be a differentiating strategy among different biosimilars and larger discounts over originator brands can boost greater uptake of specific biosimilars. Quotas dictate prescribing patterns in the 5EU; however, physicians show concern about switching to a biosimilar from the originator brand. The majority of KOLs interviewed by GlobalData indicated that they used biosimilars mostly for new patients. KOLs also cited reluctance to switch existing patients to biosimilars, highlighting that they did not want to change a biologic treatment that was working for the patient.
Other reasons against switching included lack of incentives for physicians, lack of switching data, and nocebo effects.Biogen, Sandoz, Pfizer, and Amgen are dominating the immunology biosimilars field. The immunology biosimilars space is dominated in developed markets by established brand names, including Biogen, Sandoz, Pfizer, and Amgen.
In India and South Korea, major biosimilar players include Celltrion, Cipla, and Zydus Cadila.